The U.S. Food and Drug Administration approved daraxonrasib on August 26, giving eligible adults with advanced pancreatic cancer a new treatment that directly targets a major pathway driving the disease. Sold by Revolution Medicines as Rasonque, the oral medicine follows a clinical trial in which patients lived longer than those receiving standard chemotherapy. The approval brings the treatment beyond research settings, while its use remains limited to the patients described in the FDA's authorization.
Rasonque is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy or are not candidates for treatment combining multiple systemic agents. Metastatic disease means the cancer has spread beyond its original location. The authorization concerns this advanced form of pancreatic cancer and should not be read as approval for every stage or every pancreatic tumor.
The central evidence came from RASolute 302, an international phase 3 study involving 500 previously treated patients. Researchers randomly assigned participants to daraxonrasib or a standard chemotherapy regimen selected by their physician. According to the FDA, the trial was open-label, meaning the assigned treatments were known, while an independent blinded review assessed disease progression. This design allowed investigators to compare the targeted medicine with established second-line treatment.
Median overall survival was 13.2 months in the daraxonrasib group and 6.7 months in the chemotherapy group. Median progression-free survival, the time before the disease worsened or a patient died, was 7.2 months and 3.6 months, respectively. The survival figures describe the middle of each group's outcomes, rather than the length of time any individual patient can expect to live. Both comparisons favored daraxonrasib in the trial.
The drug addresses RAS signaling, a pathway that helps regulate cell growth and can drive cancer when altered. Dana-Farber Cancer Institute explained that daraxonrasib interacts with another protein, cyclophilin A, to block signaling from RAS proteins. More than 90% of pancreatic cancers have cancer-driving mutations in KRAS, part of the RAS gene family, according to the institute. Developing a medicine capable of interrupting that process has been a longstanding challenge.
Dana-Farber's Brian Wolpin, who led the pivotal study, described the approval as a major advance after years of difficulty targeting RAS in this disease. The institute reported that the trial enrolled patients in North America, Europe and Asia, all previously treated with one chemotherapy line for metastatic cancer. Its findings had been presented at the American Society of Clinical Oncology's annual meeting and published in The New England Journal of Medicine before the regulatory decision.
Treatment tolerability also contributed to interest in the medicine. Memorial Sloan Kettering Cancer Center reported that side effects caused 1.2% of daraxonrasib recipients to stop treatment, compared with 11.2% of chemotherapy recipients in the trial. Its pancreatic cancer specialist Eileen O'Reilly said patients could experience improvements in pain, eating and fatigue. Those observations add clinical context to the survival data without establishing that every patient will experience the same benefits.
The medicine still carries important safety considerations. The FDA identified warnings involving skin and soft tissue toxicity, mouth inflammation, diarrhea, gastrointestinal perforation, inflammatory lung disease and potential harm to a developing fetus. Its recommended dose is 300 milligrams taken orally once daily until the cancer progresses or toxicity becomes unacceptable. Monitoring and treatment decisions therefore remain part of cancer care even though the medicine is taken as a pill.
The approval addresses a disease with unusually limited treatment options. ABC News reported that pancreatic adenocarcinoma accounts for a relatively small share of cancer diagnoses but a disproportionate share of deaths, reflecting late detection and aggressive disease. Dana-Farber noted that many patients are diagnosed only after the cancer has invaded nearby tissue or spread elsewhere. Those features make improvements in treatment for advanced disease particularly consequential.
For eligible U.S. patients, the next step is evaluating how the new medicine fits their treatment history and clinical condition. Memorial Sloan Kettering said FDA approval enables oncologists nationwide to use the therapy and can support insurance coverage, although individual coverage arrangements still matter. Researchers now have evidence that directly blocking RAS can improve outcomes in previously treated metastatic pancreatic cancer, providing a basis for further study of this treatment approach.
Sources
1. "FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma," U.S. Food and Drug Administration, August 26, 2026.
2. "FDA approves breakthrough drug to treat advanced pancreatic cancer," ABC News, August 26, 2026.
3. "FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber," Dana-Farber Cancer Institute, August 26, 2026.
4. "FDA Approves Daraxonrasib for Pancreatic Cancer: What Patients Need To Know," Memorial Sloan Kettering Cancer Center, August 26, 2026 (updated).